Clinical Application Of Apatinib In The Treatment Of Advanced Bone And Soft Tissue Sarcoma

Objectives:To observe the efficacy and safety of apatinib in the treatment of advanced bone and soft tissue sarcoma,and to analyze the possible related factors affecting the progression-free survival of patients.Methods:21 patients with advanced bone and soft tissue sarcoma admitted to the Department of Orthopaedics,Yunnan Cancer Hospital from June 2017 to September 2018,given apatinib tablets,500 mg once daily for 28 days.For a dosing cycle.For 28 days as a course of treatment,the main efficacy index was progression free survival(PFS),and the secondary efficacy index was overall survival(OS).Clinical efficacy was evaluated according to response evaluation criteria in solid tumors(RECIST)1.1,including overall response rate(ORR),disease control rate(DCR),and according to the National Cancer Institute.(National Cancer Institute,NCI)4.0 standard follow-up observation safetyResults:All 21 patients were followed up.As of the last follow-up time,March 31,2019,there were no CR,2 patients(9.5%)with PR,7 patients with SD(33.3%),and 12 patients with PD(57.1%).The overall response rate ORR was 9.5%,the disease control rate DCR was(42.8%),the median PFS was 8 months,and the median OS was 14 months.The patient’s gender,age,ECOG score,tissue source,whether surgery,or whether chemotherapy had no statistically significant effect on PFS(P>0.05),only the history of radiotherapy before taking apatinib was a factor for patients with PFS.The effect was statistically significant(P<0.05),and patients with a history of radiotherapy had a lower PFS than patients without a history of radiotherapy.The adverse reactions of grade Ⅲ and above were followed by hand-foot syndrome(14.3%),pneumothorax(14.3%)and anemia(4.8%).Conclusion:Apatinib has a certain effect in the treatment of advanced bone and soft tissue sarcoma.The adverse reactions are generally predictable,controllable and reversible.It can be tried for patients with advanced bone and soft tissue sarcoma with good treatment adherence and no other treatment options.